Liver disease and the vascular system (LiVas)
In our group, we believe that the best way to care for our patients is to research, advance, and transform knowledge into better medicine every day
Current research
Problem
Liver diseases are highly prevalent and are associated with high morbidity and mortality. Our goal is, on the one hand, to develop new treatments for vascular diseases based on a better understanding of their pathophysiological mechanisms; and, on the other hand, to improve the management of complications of advanced liver disease, especially those resulting from portal hypertension, in order to reduce their clinical impact and improve patient prognosis.
Approach
The group integrates basic, translational, and clinical research to understand the molecular and cellular mechanisms of portal hypertension and hepatic vascular diseases. We develop innovative preclinical models, including patient-derived organ‑on‑chip systems, and incorporate advanced imaging, hemodynamics, neurological monitoring, and radiological interventional technologies. This structure enables the identification of biomarkers, the definition of new therapeutic targets, and the development of high‑impact clinical trials.
Impact
Our research has contributed to characterizing the mechanisms underlying portosinusoidal vascular disease (PSVD) and portal hypertension, to identifying biomarkers that improve diagnosis, and to leading clinical trials that transform patient management. As an ERN–Rare Liver and CSUR (Reference Centres, Services and Units) centre, we integrate molecular data, advanced imaging, hemodynamics, and clinical monitoring to enhance risk stratification and treatment. The goal is to translate mechanistic knowledge into clinical interventions that increase survival and improve quality of life.